MedPath
Found 29 clinical trials|View Analysis
Sort by:

A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors

Not Applicable
Not yet recruiting
Conditions
Stage III Esophageal Cancer
Stage IV Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIA Gastric Cancer
Stage IV Esophageal Cancer
Interventions
Dietary Supplement: basic nutrition
Dietary Supplement: oral supplement of creatine and curcumin
First Posted Date
2023-05-12
Last Posted Date
2023-05-18
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
152
Registration Number
NCT05856500

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Recruiting
Conditions
Ann Arbor Stage I Lymphoma
Chronic Lymphocytic Leukemia
Gastroesophageal Junction Adenocarcinoma
Head and Neck Carcinoma
Malignant Hepatobiliary Neoplasm
Melanoma
Stage I Pancreatic Cancer AJCC v6 and v7
Stage I Prostate Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage II Pancreatic Cancer AJCC v6 and v7
Interventions
Other: Questionnaire Administration
Procedure: Biospecimen Collection
First Posted Date
2022-04-19
Last Posted Date
2024-12-27
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
2000
Registration Number
NCT05334069
Locations
🇺🇸

OSF Saint Anthony's Health Center, Alton, Illinois, United States

🇺🇸

Carle BroMenn Outpatient Center, Bloomington, Illinois, United States

🇺🇸

Carle BroMenn Medical Center, Normal, Illinois, United States

and more 683 locations

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Not Applicable
Active, not recruiting
Conditions
Advanced Lung Cancer
Small Cell Lung Cancer Extensive Stage
Stage IV Gastric Cancer
Stage IV Hepatocellular Cancer
Unresectable Stage III Non-Small Cell Lung Cancer
Stage IV Basal Cell Carcinoma
Stage IV Esophageal Cancer
Stage IV Cutaneous Squamous Cell Carcinoma
Stage IV Renal Cell Carcinoma
Stage IV Head and Neck Squamous Cell Carcinoma
Interventions
Other: Usual Care
Other: Educational Video and QPL List
First Posted Date
2020-12-17
Last Posted Date
2023-10-23
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
210
Registration Number
NCT04670445
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Phase 2
Completed
Conditions
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Recurrent Esophageal Carcinoma
Recurrent Gastric Carcinoma
Stage IV Esophageal Cancer AJCC v7
Stage IV Gastric Cancer AJCC v7
Unresectable Esophageal Carcinoma
Interventions
First Posted Date
2017-06-22
Last Posted Date
2024-01-23
Lead Sponsor
George Albert Fisher
Target Recruit Count
3
Registration Number
NCT03196232
Locations
🇺🇸

Stanford University, School of Medicine, Palo Alto, California, United States

Chemotherapy with or Without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer

Phase 2
Recruiting
Conditions
Gastric Adenocarcinoma
Oligometastasis
Stage IV Esophageal Adenocarcinoma AJCC V7
Stage IV Esophageal Cancer AJCC V7
Stage IV Gastric Cancer AJCC V7
Interventions
Drug: Capecitabine
Drug: Chemotherapy
Procedure: Conventional Surgery
Drug: Fluorouracil
Radiation: Radiation Therapy
First Posted Date
2017-05-19
Last Posted Date
2024-10-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
100
Registration Number
NCT03161522
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Not Applicable
Conditions
Progesterone Receptor Negative
Progressive Disease
Stage IIA Rectal Cancer
Stage IIB Rectal Cancer
Stage III Non-Small Cell Lung Cancer
Head and Neck Carcinoma
Limited Stage Small Cell Lung Carcinoma
Myelodysplastic Syndrome
Stage II Pancreatic Cancer
Stage IIA Pancreatic Cancer
Interventions
Other: Best Practice
Other: Laboratory Biomarker Analysis
Procedure: Supportive Care
Other: Survey Administration
First Posted Date
2017-05-16
Last Posted Date
2022-02-03
Lead Sponsor
Stanford University
Target Recruit Count
128
Registration Number
NCT03154190
Locations
🇺🇸

Virginia K Crosson Cancer Center, Fullerton, California, United States

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1
Active, not recruiting
Conditions
Recurrent Gastroesophageal Junction Adenocarcinoma
Stage III Esophageal Cancer AJCC v7
Metastatic Gastric Carcinoma
Recurrent Esophageal Carcinoma
Stage III Gastric Cancer AJCC v7
Stage IV Esophageal Cancer AJCC v7
Metastatic Esophageal Carcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Esophageal Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2017-01-02
Last Posted Date
2024-08-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT03008278
Locations
🇺🇸

City of Hope Antelope Valley, Lancaster, California, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

City of Hope Upland, Upland, California, United States

and more 29 locations

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Phase 1
Terminated
Conditions
Colorectal Adenocarcinoma
Metastatic Gastric Carcinoma
Metastatic Cholangiocarcinoma
Metastatic Esophageal Carcinoma
Metastatic Pancreatic Adenocarcinoma
Stage IV Gastric Cancer AJCC v7
Stage IV Pancreatic Cancer AJCC v6 and v7
Stage IV Esophageal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Metastatic Colorectal Carcinoma
Interventions
Biological: Adoptive Immunotherapy
Biological: Aldesleukin
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
First Posted Date
2016-05-02
Last Posted Date
2020-10-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT02757391
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Phase 1
Active, not recruiting
Conditions
Advanced Bile Duct Carcinoma
Stage IIB Pancreatic Cancer AJCC v6 and v7
Stage II Esophageal Cancer AJCC v7
Stage II Pancreatic Cancer AJCC v6 and v7
Stage IIA Esophageal Cancer AJCC v7
Stage IIA Pancreatic Cancer AJCC v6 and v7
Stage IIB Esophageal Cancer AJCC v7
Stage III Colon Cancer AJCC v7
Stage III Gastric Cancer AJCC v7
Stage III Liver Cancer
Interventions
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Ropidoxuridine
First Posted Date
2015-03-06
Last Posted Date
2024-03-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT02381561
Locations
🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Phase 1
Withdrawn
Conditions
Stage IIIA Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Adenocarcinoma of the Esophagus
Intestinal Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction
Mixed Adenocarcinoma of the Stomach
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer
Interventions
Drug: c-Met inhibitor AMG 337
Other: placebo
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2015-01-26
Last Posted Date
2023-05-25
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT02344810
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath